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Introduction {#sec001}
============

Menopause refers to the cessation of ovarian function that leads to the termination of the menstrual cycle and is accompanied by decreased estrogen levels, increased follicle stimulating hormone and luteinizing hormone levels, and significant changes in endocrine secretion \[[@pone.0228559.ref001]\]. This leads to serious pathophysiological changes such as depression, anxiety, sleep disorders, hot flashes, night sweats, and menstrual disorders \[[@pone.0228559.ref002]\]. In addition, the risk of metabolic abnormalities in menopausal women increases significantly \[[@pone.0228559.ref003]--[@pone.0228559.ref006]\]. For example, a cross-sectional and longitudinal analysis has shown that plasma intermediate-density lipoprotein (IDL) and LDL levels are higher in menopausal women than in women of childbearing age \[[@pone.0228559.ref003]\]. Another prospective population study has shown that menopause and aging are independently correlated with body mass index (BMI) increase \[[@pone.0228559.ref004]\]. Insulin resistance in menopausal women is found to increase the incidence of type II diabetes (T2DM) \[[@pone.0228559.ref005]\], and significantly increase the risk of metabolic syndromes (MetS) \[[@pone.0228559.ref006]\]. Thus, the decline in estrogen level in menopause is closely related to metabolic abnormalities.

Oxidative stress is defined as an imbalance between oxidation and anti-oxidation in the body where the endogenous antioxidants are not able to counteract the oxidative dysregulation of lipids, protein, DNA and cellular structures \[[@pone.0228559.ref007]\]. Oxidative stress has been found to be closely related to metabolism in recent years \[[@pone.0228559.ref008], [@pone.0228559.ref009]\]. For instance, high concentration of hydrogen peroxide (H~2~O~2~) promotes insulin signaling, inducing insulin-like metabolism to increase glucose uptake by adipocytes and muscles and stimulating glucose transporter type-4 (GLUT-4) translocation and lipid synthesis in adipocytes \[[@pone.0228559.ref008]\]. In obese populations, the abnormal secretion of anti-inflammatory factors, such as resistin, visfatin, and adiponectin, and pro-inflammatory factors, such as tumor necrosis factor alpha (TNF-α), interleukin (IL)-1 and IL-6, in adipose tissues causes an increase in reactive oxygen species (ROS) in the body \[[@pone.0228559.ref009]\].

Nuclear factor E2-related factor 2 (NRF2) is an oxidative stress protein sensor that plays critical roles in oxidative defense, inflammatory reaction, and anti-apoptosis in cells \[[@pone.0228559.ref010]\]. Recent studies showed that NRF2 also affects energy metabolism and activates extracellular signal-regulated kinase (ERK) signaling to participate in insulin resistance in cardiomyocytes; activated NRF2 enhances insulin receptor sensitivity and increases glucose uptake \[[@pone.0228559.ref011]\]. In addition, a significant reduction of abdominal fat was found in *Nrf2*-knockout mice, and the mRNA expression of genes involved in fat synthesis in *Nrf2*-knockout mice was reduced, indicating that NRF2 plays a negative regulatory role in lipid metabolism \[[@pone.0228559.ref012]\]. However, another study showed markedly accelerated adipogenesis upon stimulation in *Nrf2* -/- embryonic fibroblast cells (MEFs), while *Keap1* -/- MEFs differentiated slowly compared to their congenic wild-type MEFs \[[@pone.0228559.ref013]\]. Therefore, the effects of *Nrf2* gene on energy metabolism in different models require further clarification.

Menopause changes the metabolic state due to changes in the endocrine environment. As energy metabolism is closely related to oxidative stress, *Nrf2* gene deletion may affect the metabolism of menopausal women through various signaling pathways. Ovariectomy is the most common method of establishing an animal model of menopause. Hence, this study established an *Nrf2*-knockout menopausal mouse model to evaluate the effect of *Nrf2* deficiency on glucose and lipid metabolism in menopausal females. The results of this study further our understanding of the molecular mechanisms and genetic basis of metabolic disorders in menopausal women.

Methods {#sec002}
=======

1. Experimental subjects and grouping {#sec003}
-------------------------------------

This animal study was approved by the Ethics Committee of the Third Affiliated Hospital of Guangzhou Medical University (No.2018\[026\]). Experiments were conducted according to the National Institutes of Health guide for the care and use of Laboratory animals, and all efforts were made to minimize animal suffering. Specific-pathogen free wide-type C57BL/6J female mice were purchased from the Guangdong Medical Laboratory Animal Center (Guangzhou, China). *Nrf2*-deficient mice were purchased from the Jackson Laboratory (Bar Harbor, ME, USA) on an 129X B6 F1 background and were then backcrossed onto a C57BL6/J strain for more than 10 generations \[[@pone.0228559.ref014]\]. All female mice were housed in the specific pathogen-free animal facility in the Laboratory Animal Center of South China Agriculture University (Guangzhou, China), and maintained on a controlled light cycle schedule of 12:12 h (light/dark) at 24°C with chow diet ad libitum. Genotypes of all animals were determined by analysis of DNA extracted from mouse tails.

The female mice were divided into four groups (7--8 animals for each group): wild-type control (WT-CON), wild-type ovariectomy (WT-OVX), *Nrf2−/−* control (KO-CON) and *Nrf2−/−* ovariectomy (KO-OVX). Ovariectomy was performed in the WT-OVX and KO-OVX groups once the mice reached 15--16 weeks old, while a simulated operation was performed in the WT-CON and KO-CON groups. For surgery, mice were anaesthetized with an IP injection of 100 mg/kg ketamine, and postoperative recovery of all animals was monitored. Vaginal smears were performed in all groups of female mice for seven consecutive days at four weeks postoperatively, followed by staining the smear samples with methylene blue to observe changes in the estrous cycle in mice \[[@pone.0228559.ref015]\].

2. Experimental sample collection and preparation of bodyweight curve {#sec004}
---------------------------------------------------------------------

All experimental mice were weighed before surgery and in the postoperative 1, 3, 5, 7, 9 weeks after overnight fasting. About 100 ul of blood samples were collected through retro-orbital (eyelid blood collection) before surgery and at the end of each time point postoperatively. When sacrificed at postoperative 9 week, all animals were euthanized using CO~2~ and 500 ul of blood was collected by eyeball dissection, followed by dissecting the brain on ice and storage of the tissues at −80°C for later use. The collected peripheral blood samples were let stand at room temperature for an hour, followed by centrifuging at 775g for 15 min to collect and storage of the serum at −80°C for later use.

3. Detection of estrogen levels {#sec005}
-------------------------------

Serum hormone estradiol (E2) form preoperative and postoperative week 5 was detected using an enzyme-linked bio-estradiol (E2) ELISA kit (Shanghai Enzyme-linked Biotechnology Co., Ltd., Shanghai, China) by adding 50 μl of individual standards and samples into each standard and sample well, respectively, and not adding any solution in the blank controls. After adding 100 μl horseradish peroxidase (HRP)-labeled E2 antibodies into each well to incubate at 37°C for 60 min, the ELISA plate was washed and 50 μl of coloring solutions A and B were independently added into each well to incubate at 37°C for 10 min. After adding 50 μl stopping solution to terminate the reaction, the absorbance of each well was measured with an ELx808 microplate reader (Biotek, USA) to calculate the sample concentrations.

4. Detection of glucose and lipid metabolism indices {#sec006}
----------------------------------------------------

Serum low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglycerides (TG), total cholesterol (T-CHO) and glucose (GLU) were measured using the corresponding detection kits (Jiancheng Bioengineering Institute, Nanjing, China) preoperatively and at postoperative weeks 1, 3, 5, 7, and 9, strictly in accordance with the manufacturer's instructions. The detection range, sensitivity, and the intra and inter assay coefficient of variation of all biochemical and ELISA kits were provided in [S1 Table](#pone.0228559.s002){ref-type="supplementary-material"}.

5. Oxidative stress marker, malondialdehyde (MDA) {#sec007}
-------------------------------------------------

Serum MDA concentration at postoperative week 9 was measured using an MDA kit (Cloud-Clone Corp., Wuhan, China) by adding 50 μl standards or serum samples into standard or blank control wells, respectively. Then, 50 μl sample diluting solution was added to the blank control well. Subsequently, 50 μl of biotin-labeled antigen was added to each well to incubate at room temperature for 60 min, followed by washing each well and adding 100 μl HRP-labeled avidin to incubate for 30 min. After washing the ELISA plate, 90 μl color developing solution was added to each well to incubate for 10 min, followed by adding 50 μl stopping solution per well to stop the reaction and reading the absorbance using an ELx808 microplate reader (Biotek, USA) to calculate the individual sample concentration.

6. Detection of neurotransmitters {#sec008}
---------------------------------

Brain tissues stored at −80°C were weighed and cell lysis buffer (0.1% SDS + 0.05% Triton-X) was added in a weight ratio of 1 g to 9 ml buffer for homogenization. The brain homogenates were then centrifuged at 3,000 rpm for 20 min to collect the supernatants for the detection of mouse dopamine (DA) and serotonin (5-hydroxytryptamine, 5-HT), using the DA and 5-HT ELISA kits (Shanghai Enzyme-linked Biotechnology Co., Ltd, Shanghai, China) strictly in accordance with the manufacturer's instructions.

7. Statistical analysis {#sec009}
-----------------------

All statistical analyses were performed using Graphpad Prism 5.0 (La Jolla, CA, USA). Data are presented as mean ± standard error (SEM). One-way ANOVA with Bonferroni\'s Multiple comparison test or Kruskal-Wallis test with Dunn\'s Multiple comparison test was used for ordinary or non-parametric data, as specified in the figure legends. Statistical significance was defined as *P* \< 0.05.

Results {#sec010}
=======

1. Changes in estrogen levels and the estrous cycle in different groups of mice {#sec011}
-------------------------------------------------------------------------------

This study compared the preoperative and postoperative estrogen levels and calculated the changed estrogen rate of each mouse at postoperative week 5. The results showed that the change rate of estrogen levels of the WT-OVX and KO-OVX groups were significantly lower than that of the WT-CON and KO-CON groups (WT-CON 60.12% ± 124.9%, WT-OVX -21.02% ± 19.32%, KO-CON 34.03% ± 47.50%, and KO-OVX -27.02% ± 14.19, *P*\< 0.05). No significant changes in different genotypes of the ovariectomy and control groups were found ([Fig 1a](#pone.0228559.g001){ref-type="fig"}). In addition, postoperative methylene blue staining of the continuous vaginal smears of the WT-OVX and KO-OVX groups demonstrated a change in the estrous condition, as a large number of white blood cells or a small number of keratinized epithelial cells were observed ([Fig 1b](#pone.0228559.g001){ref-type="fig"}). However, normal estrous changes were observed in the mice of the WT-CON and KO-CON groups, and a large number of keratinized epithelial cells were observed under light microscopy ([Fig 1b](#pone.0228559.g001){ref-type="fig"}).

![Changes of estrogen levels and vaginal smears in different groups of mice.\
WT-CON: wild-type control, WT-OVX: wild-type ovariectomy, KO-CON: *Nrf2−/−* control, KO-OVX: *Nrf2−/−* ovariectomy. (a) The change rate of estrogen levels before ovariectomy and at postoperative week 5. Results are shown as mean ± SEM. \* *P* \< 0.05 analyzed by Kruskal-Wallis test with Dunn\'s Multiple comparison test. (b) Results of vaginal smears in different groups of mice at postoperative week 4--5. Vaginal smears in the left figures represent the morphologies of estrus, with a large number of keratinized epithelial cells observed under light microscopy. Vaginal smears in the right figures represent the morphologies of diestrus, with a large number of white blood cells and a small number of keratinized epithelial cells. The red arrows represent keratinized epithelial cells and the yellow arrows represent white blood cells.](pone.0228559.g001){#pone.0228559.g001}

2. Comparison of MDA levels in different groups of mice {#sec012}
-------------------------------------------------------

MDA is one of the products of oxidative stress, reflecting the peroxidation level of the body. This study observed the changes in oxidative stress levels in different groups by detecting the serum MDA level of mice. The results showed that, compared to the WT-CON group, the serum MDA levels increased in the WT-OVX and KO-CON groups, but decreased in the KO-OVX group, though no statistical significance was reached yet ([Fig 2](#pone.0228559.g002){ref-type="fig"}).

![Comparison of malondialdehyde (MDA) levels in different groups of mice.\
WT-CON: wild-type control, WT-OVX: wild-type ovariectomy, KO-CON: *Nrf2−/−* control, KO-OVX: *Nrf2−/−* ovariectomy. Serum MDA concentration at postoperative week 9 was measured in different groups. Results are shown as mean ± SEM.](pone.0228559.g002){#pone.0228559.g002}

3. Body weight changes in different groups of mice {#sec013}
--------------------------------------------------

Body weight curves prepared by weighing each group of mice weekly showed that weight gain occurred in the WT-OVX and KO-OVX groups relative to the WT-CON and KO-CON groups ([Fig 3b](#pone.0228559.g003){ref-type="fig"}). No significant difference of the weight gain rate was found between the WT-CON and KO-CON groups, but OVX groups had increased weight compared to the counterpart CON groups ([Fig 3b and 3a](#pone.0228559.g003){ref-type="fig"}, *P* \< 0.05 and *P* \< 0.01). By calculating the rate of weight gain from the preoperative time to postoperative week 9 in different groups, we found that the weight gain rates of the KO-OVX was significantly higher than that in the corresponding KO-CON and WT-CON groups after postoperative week 4 ([Fig 3b](#pone.0228559.g003){ref-type="fig"}), and the weight gain rate of KO-OVX was the greatest and was significantly different from the WT-CON and KO-CON group (WT-CON 6.02% ± 2.95%, WT-OVX 18.55% ± 7.40%, and KO-CON 5.25% ± 5.08%, KO-OVX 27.35% ± 10.04%).

![Changes in bodyweight in different groups of mice.\
WT-CON: wild-type control, WT-OVX: wild-type ovariectomy, KO-CON: *Nrf2−/−* control, KO-OVX: *Nrf2−/−* ovariectomy. (a) The weight gain in different groups of mice preoperatively and at postoperative week 9. \**P* \< 0.05; \*\**P* \< 0.01. (b). Changes in bodyweight curve of different groups of mice during 9 weeks after ovariectomy. \**P* \< 0.05; \*\**P* \< 0.01 (KO-OVX vs KO-CON); ^\#^ *P* \< 0.05; ^\#\#^*P* \< 0.01 (KO-OVX vs WT-CON). Results are shown as mean ± SEM. Data were analyzed by One-way ANOVA with Bonferroni\'s Multiple comparison test.](pone.0228559.g003){#pone.0228559.g003}

4. Time-varying maps of metabolic indicators in different groups of animals {#sec014}
---------------------------------------------------------------------------

The changes in the serum LDL, HDL, TG, T-CHO, and GLU concentrations were measured preoperatively and at postoperative weeks 1, 3, 5, 7, and 9, and compared in different groups of mice ([Fig 4a--4e](#pone.0228559.g004){ref-type="fig"}).

![Changes in different metabolic indicators in different groups of mice over time.\
WT-CON: wild-type control, WT-OVX: wild-type ovariectomy, KO-CON: *Nrf2−/−* control, KO-OVX: *Nrf2−/−* ovariectomy. Curves showing the changes in serum metabolite levels preoperatively (week 0) and at postoperative week 1, 3, 5, 7, and 9 in different groups of mice. (a) Change curve of glucose levels. \**P* \< 0.05; \*\**P* \< 0.01 (KO-CON vs WT-CON); ^\#^*P* \< 0.05 (KO-OVX vs KO-CON). (b) Change curve of T-CHO levels. \**P* \< 0.05; \*\**P* \< 0.01 (KO-CON vs WT-CON); ^\#^*P* \< 0.05; ^\#\#^*P* \< 0.01 (KO-OVX vs WT-OVX). (c) Change curve of TG levels. \**P* \< 0.05; \*\**P* \< 0.01 (KO-CON vs WT-CON); ^\#^*P* \< 0.05; ^\#\#^*P* \< 0.01 (KO-OVX vs WT-OVX). (d) Change curve of LDL levels. \**P* \< 0.05; \*\**P* \< 0.01 (KO-OVX vs KO-CON); ^\#^*P* \< 0.05; ^\#\#^*P* \< 0.01 (WT-OVX vs WT-CON). (e) Change curve of HDL levels. Results are shown as mean ± SEM. Data were analyzed by One-way ANOVA with Bonferroni\'s Multiple comparison test.](pone.0228559.g004){#pone.0228559.g004}

Our results showed that the serum GLU of the KO-CON group was significantly lower than that of the WT-CON group at postoperative weeks 1, 3, and 9 ([Fig 4a](#pone.0228559.g004){ref-type="fig"}, *P* \< 0.05), and also had low tendency at postoperative weeks 5, and 7. However, the serum GLU of the KO-OVX group was significantly higher than that of the KO-CON group at postoperative week 3 and 5 (*P* \< 0.05), and was marginally higher at postoperative week 7 and 9, while there was little change between WT-OVX and WT-CON groups ([Fig 4a](#pone.0228559.g004){ref-type="fig"}).

The serum T-CHO levels of the KO-CON group was significantly lower than that of the WT-CON group at postoperative weeks 1, 3, and 5 ([Fig 4b](#pone.0228559.g004){ref-type="fig"}, *P* \< 0.05), and that of the KO-OVX groups were significantly lower than that of the WT-OVX groups after ovariectomy ([Fig 4b](#pone.0228559.g004){ref-type="fig"}, all *P* \< 0.05). However, there was little change of serum T-CHO levels between OVX groups and counterpart CON groups in WT and KO mice ([Fig 4b](#pone.0228559.g004){ref-type="fig"}).

In addition, the KO-CON group also had significantly lower levels of serum TG compared to the WT-CON group at postoperative weeks ([Fig 4c](#pone.0228559.g004){ref-type="fig"}, *P* \< 0.05), and that of the KO-OVX group were significantly lower than that of the WT-OVX group after ovariectomy ([Fig 4c](#pone.0228559.g004){ref-type="fig"}, all *P* \< 0.05), and. However, there was little change between CON groups and counterpart OVX groups in WT and KO mice respectively ([Fig 4c](#pone.0228559.g004){ref-type="fig"}).

Comparison between the KO and WT groups showed that the serum LDL levels of the KO-CON group was significantly higher than that of the WT-CON group during postoperative period ([Fig 4d](#pone.0228559.g004){ref-type="fig"}, all *P* \< 0.05). Comparison the preoperative groups and counterpart postoperative groups, the LDL levels in the WT-OVX significantly increased ([Fig 4d](#pone.0228559.g004){ref-type="fig"}, all *P* \< 0.05), but the LDL levels in the KO-OVX group significantly decreased after ovariectomy ([Fig 4d](#pone.0228559.g004){ref-type="fig"}, all *P* \< 0.05). However, the serum HDL levels of has no statistically significant difference among all groups ([Fig 4e](#pone.0228559.g004){ref-type="fig"}).

5. Changes in neurotransmitters in different groups {#sec015}
---------------------------------------------------

To evaluate the effect of menopause on the mental status, this study examined the levels of 5-HT and DA in brain tissues. The inhibitory neurotransmitter, 5-HT, of the KO-OVX group decreased after ovariectomy compared to the KO-CON group, which was significantly lower than that of the WT-CON and WT-OVX groups ([Fig 5a](#pone.0228559.g005){ref-type="fig"}, *P* \< 0.05). The test value (ng/ml) showing as 37.88 ± 13.06, 37.18 ± 14.24, 31.54 ± 8.39, and 25.07 ± 3.25 in the WT-CON, WT-OVX, KO-CON, and KO-OVX groups, respectively. Another excitatory neurotransmitter, DA, was found no significant difference in the brain tissues in different groups ([Fig 5b](#pone.0228559.g005){ref-type="fig"}).

![Concentrations of neurotransmitters in the brain tissues of different groups of mice.\
WT-CON: wild-type control, WT-OVX: wild-type ovariectomy, KO-CON: *Nrf2−/−* control, KO-OVX: *Nrf2−/−* ovariectomy. (a) Concentrations of 5-hydroxytryptamine (5-HT) in the brain tissues of different groups of mice at postoperative week 9. (b) Dopamine (DA) concentrations in the brain tissues of different groups of mice at postoperative week 9. Results are shown as mean ± SEM. \**P* \< 0.05 analyzed by One-way ANOVA with Bonferroni\'s Multiple comparison test.](pone.0228559.g005){#pone.0228559.g005}

Discussion {#sec016}
==========

This study used ovariectomy to establish a menopausal mouse model and showed that the KO menopausal mouse model had significantly more weight gain, and significantly different glucose and LDL metabolism than the WT menopausal mice. In addition, the 5-HT levels in the brains of the KO menopausal mouse model were significantly lower than that of the WT menopausal mice. Therefore, an *Nrf2* deletion is a genetic factor that causes susceptibility to menopausal female obesity and its induction mechanism is possibly different from a simple decline in estrogen level.

After ovariectomy surgery, both KO mice and WT mice had a significant decrease in estrogen levels ([Fig 1](#pone.0228559.g001){ref-type="fig"}). Numerous studies have shown that estrogen can effectively regulate weight gain \[[@pone.0228559.ref016]--[@pone.0228559.ref018]\]. In a longitudinal study, increased waist circumference, BMI, and fat mass and reduced skeletal muscle mass were found in menopausal women, which are associated with changes in menopausal hormone levels \[[@pone.0228559.ref019]\]. A study has shown a similar conclusion that postmenopausal women are five times more likely to have central obesity than premenopausal women \[[@pone.0228559.ref020]\]. In this study, we found that the body weight gain of the menopausal mouse models showed a significant increase compared with the control groups, with the body weight increasing by 18%--27% at postoperative week 9, which proves that a decline in estrogen level has a negative effect on bodyweight after menopause ([Fig 3](#pone.0228559.g003){ref-type="fig"}).

Studies of molecular mechanisms of menopausal weight gain have shown menopausal weight gain is closely related to the changes in lipid metabolism. A population survey has confirmed that T-CHO, LDL, and TG peak in menopausal women, which is associated with decreased E2 and increased follicle stimulating hormones \[[@pone.0228559.ref021]\]. In addition, the changes in T-CHO and LDL are significantly related to the changes in bodyweight \[[@pone.0228559.ref021]\]. Our data showed that the LDL level of the WT ovariectomized mice was significantly higher than that of the WT control mice, but that of T-CHO and TG did not reach statistical significance ([Fig 4b, 4c and 4d](#pone.0228559.g004){ref-type="fig"}). In addition, in menopausal animal model, it was reported that ovariectomy may have an effect on glucose metabolism and insulin resistance \[[@pone.0228559.ref022]\]. In our study, no significant change in blood glucose levels was found before and after ovariectomy in WT mice, however, in KO mice, ovariectomy led to significantly elevated glucose levels, which may partially account for their rapid weight gains.

Comparison of the metabolic data between KO control group and WT control group demonstrated that the lipid metabolism was significantly different ([Fig 4](#pone.0228559.g004){ref-type="fig"}). The T-CHO and TG levels of the KO mice were significantly lower, while the LDL level of the KO mice was significantly higher than that of the WT mice, suggesting *Nrf2* plays important roles in the regulation of lipid metabolism ([Fig 4b, 4c and 4d](#pone.0228559.g004){ref-type="fig"}). Previous studies have shown that a *Nrf2* deletion improves insulin resistance, inhibits lipid synthesis and regulates the expression of regulators of lipid synthesis \[[@pone.0228559.ref023]\]. In addition, these *Nrf2* KO mice had reduced fat mass, smaller adipocytes, inhibited lipogenesis in adipocytes \[[@pone.0228559.ref024], [@pone.0228559.ref025]\], and decreased blood glucose and cholesterol in serum, liver and adipose tissues \[[@pone.0228559.ref012], [@pone.0228559.ref026]\]. Therefore, *Nrf2* deletion effectively inhibits lipid synthesis in mice model before overiecomy ([Fig 4b, 4c and 4d](#pone.0228559.g004){ref-type="fig"}).

However, once the KO mice were ovariectomized, the T-CHO, TG and HDL levels had no significant changes compared with the KO control mice ([Fig 4b, 4c and 4d](#pone.0228559.g004){ref-type="fig"}). Notably, LDL levels in the KO mice were dramatically reduced after ovariectomy, when the estrogen level was reduced; while the LDL levels of the WT mice were sharply increased after the ovariectomy ([Fig 4d](#pone.0228559.g004){ref-type="fig"}). Although a dual role of NRF2 during metabolic dysregulation was reported as increasing lipid accumulation in liver and white adipose tissue but preventing lipid accumulation in obese mice \[[@pone.0228559.ref027]\], the exact LDL levels in *Nrf2*-knockout mice had no report so far. In this study, unchanged levels of the T-CHO, TG and HDL but elevated LDL was observed in KO mice after ovariectomy suggested that a decline in estrogen levels did not seem to completely reverse the inhibition of lipid synthesis caused by *Nrf2* deletion. For further elucidation, the adiposity of these animals should be evaluated to explain whether a greater weight gain in KO ovariectomized mice also mean fat accretion.

Previous studies have reported that 5-HT levels in cerebral spinal fluid reduced in a menopausal mouse model \[[@pone.0228559.ref028]\], and serum 5-HT concentrations were negatively associated with age, weight, BMI, fat mass in postmenopausal women \[[@pone.0228559.ref029]\]. In this study, we did not find significant alteration of 5-HT in WT mice after ovariectomy in the brain tissue homogenate ([Fig 5a](#pone.0228559.g005){ref-type="fig"}). However, KO menopausal mice had a significant reduction of 5-HT compared to WT groups ([Fig 5a](#pone.0228559.g005){ref-type="fig"}). As an inhibitory neurotransmitter, 5-HT is involved in energy metabolism by not only limiting food intake by suppressing appetite, but also participating in energy metabolism \[[@pone.0228559.ref030]\], and drugs that enhance 5-HT delivery have been extensively used to clinically treat obesity \[[@pone.0228559.ref031]\]. Therefore, the increased bodyweight of mice in the KO-OVX observed in this study might be associated with the significant reduction of brain 5-HT level. As the combination of *Nrf2* deletion and a decline in estrogen level leads to a more pronounced decrease in 5-HT levels, thereby increasing the susceptibility to obesity. Therefore, whether *Nrf2* deletion in ovariectomized female mice can alter their food intake and cause hyperphagia should to be further confirmed.

Although global knock-out of *Nrf2* in mice protects against weight gain and obesity, on different background, the exact effects of *Nrf2* are still controversial \[[@pone.0228559.ref012], [@pone.0228559.ref032], [@pone.0228559.ref033]\]. For instance, in diet-induced obesity mice model, adipose-specific *Nrf2* KO mice showed reduced blood glucose, reduced number but increased size of adipocytes \[[@pone.0228559.ref034]\]. In the Lepob/ob mice (OB) model, ablation of *Nrf2* led to reduced white adipose tissue mass, but resulted in an even more severe metabolic syndrome with aggravated insulin resistance, hyperglycemia, and hypertriglyceridemia \[[@pone.0228559.ref023], [@pone.0228559.ref027]\]. Based on current data, it was supposed that the superposition of *Nrf2* deficiency and a decline in estrogen level promoted weight gain *in vivo* ([Fig 3](#pone.0228559.g003){ref-type="fig"}), and there might be complex interactions between these two molecules on metabolism regulation.

Recently, increasing evidence has demonstrated that *Nrf2* signaling is antagonistic to estrogen signaling in hepatic fat metabolism \[[@pone.0228559.ref035], [@pone.0228559.ref036]\]. For instance, a high-fat diet and simultaneous administration of exogenous estrogen reduced the hepatic TG levels by 49% and 90% in WT and KO nonalcoholic fatty liver disease mice, respectively, which suggests that *Nrf2* deletion significantly amplifies the inhibitory effect of estrogen on adipogenesis \[[@pone.0228559.ref035]\]. At the same time, administration of 17β-E2 in ovariectomized mice significantly reduces ROS production and upregulates *Nrf2* mRNA and protein expression, which induces the expression of phase II antioxidant enzymes \[[@pone.0228559.ref036]\]. Therefore, besides *Nrf2* deficiency and estrogen are both inhibitors for weight gain, they might also have interactive regulation in the energy metabolism. Based on current data, we did not know the detailed mechanisms for observed interactions yet. In addition, as *Nrf2* also coordinates the basal and stress-inducible activation of a vast array of cytoprotective genes, what are their effects on the menopausal metabolism is not uncertain and awaits further research.

Conclusions {#sec017}
===========

This study showed that compared with the corresponding WT mice, *Nrf2* KO ovariectomized mice had a greater bodyweight gain. Different from their WT counterparts, a significant increase in blood glucose level, unchanged T-CHO, TG, and HDL levels, but a significant reduction in serum LDL was found in the *Nrf* KO mice after ovariectomy. In addition, the level of the neurotransmitter 5-HT in the brain was significantly reduced in the *Nrf2* KO mice after ovariectomy. Thus, the combination of *Nrf2* deletion and a decline in estrogen level induced a significant increase in bodyweight. The mechanism may be different from weight gain caused by a simple decline in estrogen level but may be associated with the altered glucose and LDL metabolism regulation and decreased 5-HT levels.
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Kind regards,

Vanessa Souza-Mello, Ph.D.

Academic Editor

PLOS ONE

Journal Requirements:

1\. When submitting your revision, we need you to address these additional requirements. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at <http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2\. To comply with PLOS ONE submission requirements, in your Methods section, please provide additional information regarding the experiments involving animals and ensure you have included details on 1) methods of anesthesia and/or analgesia, and 2) efforts to alleviate suffering.

3\. PLOS journals require authors to make all data underlying the findings described in their manuscript fully available without restriction at the time of publication. As such, please supply the minimal data set as a new supplementary figure/table, or deposit it in a public database. (By minimal data set, we mean the values behind the graphs and charts shown in your manuscript.) For more information, please see our data availability policy at <https://journals.plos.org/plosone/s/data-availability>.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The article entitled "Nrf2 deficiency increases obesity susceptibility in a mouse menopausal model" explains the importance of Nrf2 on metabolic abnormalities in menopausal women using overiectomized mouse menopausal model. The authors show the importance of Nrf2 gene in onset of obesity, which is already known with several published articles. Obesity itself has shown to reduce Nrf2 expression, as well as Nrf2 deletion alters estrus cycle, which is validated in nrf2-/- mice. The mechanistic aspects of Nrf2 deletion on menopause is lacking. The manuscript needs some revisions,

1\. The authors need to add the references for estradiol levels, estrus cycle in Nrf2 deletion.

2\. It is known that overiectomy is done in female mice, but the authors need to mention the mouse gender used in this study?

3\. In the methodology the authors don't mention time points study but in the results section they have results at different time points (Fig. 4). This needs to be explained in the methodology.

4\. The collection of blood through retro-orbital (eyelid blood collection) which is mentioned in the methods is for end point or terminal experiments. Did the authors collect blood through this method at the end of each time point? If not how much of the serum did they use for the detection of glucose and lipid metabolism indices at each time point?

5\. Standard deviation in most of the results is more than the mean values? (Fig. 1, Fig. 3 & Fig. 4)

6\. Fig. 3b, change in body weights significance between the groups needs to be shown?

7\. In the discussion, there is a sentence which says " numerous studies have shown that estrogen......" but only one reference quoted?

Reviewer \#2: In the present study, the authors investigated the role of the Nuclear factor E2-related factor 2 (NRF2), an important oxidative stress sensor that plays regulatory role in energy metabolism, on metabolic parameters of ovariectomized menopausal model.

This study is of interest as it addresses an important biological and medical issue. On the whole, the manuscript is sound and well written but I however have some minor concerns that should be addressed by the authors before publication.

Abstract: please include p-value after differences affirmations through the abstract.

Materials & methods

The authors took in account the the National Institutes of Health guide for the care and use of Laboratory animals? Please, provide this information

Statistical analysis: in the present study the authors compared four groups, T-test seems to not be the best way to perform this analysis. ANOVA must be applied.

Please, review all numbered sections through the manuscript.

Results.

Please, provide food intake/energy intake of the animals. Is it hyperphagia presented in ovariectomized mice?

4\. Time-varying maps of metabolic indicators in different groups of animals: what the author's means with "various metabolic substances"? Unclear... please rephrase

Materials & method.

Centrifugation speed should be expressed as g instead of rpm as rpm depends on the diameter of the rotor. Of the centrifuge. Table is available on the web to do this conversion using the speed in rpm and the diameter of the rotor.

Materials & methods: Please specify the sensitivity of the assay (i.e. the LOD) and the intra assay coefficient of variation of all ELISA assay.

Were the main white adipose tissue fat pads dissected out to evaluate the adiposity of the animals. Does a greater weight gain in the groups also mean fat accretion?

If the adipose tissue accretion is reduced in some groups (here we need food intake to discuss) there is an "energetic paradox" according to the first law of thermodynamics... (Energy intake = Energy expenditure + Energy stored)

Nuclear factor E2-related factor 2 (Nrf2) is a transcription factor that coordinates the basal and stress-inducible activation of a vast array of cytoprotective genes. Understanding the regulation of Nrf2 activity and downstream pathways has major implications for human health, include in menopause woman.

In the presented work, the authors showed the impact of NRF2 depletion on oxidative stress but not in antioxidant response. How this could limit the conclusion of the work?

Also in discussion section, the evidence of NRF2 and energy metabolism should be clearer.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Click here for additional data file.
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Author response to Decision Letter 0

19 Dec 2019

Dear editor,

Thanks for timely review on our manuscript entitled \"NRF2 deficiency increases obesity susceptibility in a mouse menopausal model\". We have submitted the revised manuscript and marked copy with track changes in red. Below is the point-to-point response to the comments of the reviewers and editorial requests. Thank you very much for your kindly helps and looking forward to hear from you soon.

Best regards,

Bolan Yu

Point to point response

Editorial requests:

1.Two different reviewers with expertise in the study subject agreed that a major review is needed. Please pay special attention to statistical analysis, which must be changed as well as other comments on methods and results/ discussion.

We have revised the entire manuscript according to the reviewers' comments, and statistical analysis was performed using One-way ANOVA.

Review Comments to the Author

Reviewer \#1: The article entitled "Nrf2 deficiency increases obesity susceptibility in a mouse menopausal model" explains the importance of Nrf2 on metabolic abnormalities in menopausal women using overiectomized mouse menopausal model. The authors show the importance of Nrf2 gene in onset of obesity, which is already known with several published articles. Obesity itself has shown to reduce Nrf2 expression, as well as Nrf2 deletion alters estrus cycle, which is validated in nrf2-/- mice. The mechanistic aspects of Nrf2 deletion on menopause is lacking. The manuscript needs some revisions,

1\. The authors need to add the references for estradiol levels, estrus cycle in Nrf2 deletion.

Based on our knowledge, we haven\'t found the reference for estradiol and estrus cycle in Nrf2 KO mice yet, nor did evidence suggest that Nrf2 deletion may cause altered estrus cycle.

2\. It is known that overiectomy is done in female mice, but the authors need to mention the mouse gender used in this study?

Thanks for the suggestion, we have added the gender for the mouse.

3\. In the methodology the authors don't mention time points study but in the results section they have results at different time points (Fig. 4). This needs to be explained in the methodology.

We have added the time points in the methods section (eg. Experimental sample collection and preparation of bodyweight curve).

4\. The collection of blood through retro-orbital (eyelid blood collection) which is mentioned in the methods is for end point or terminal experiments. Did the authors collect blood through this method at the end of each time point? If not how much of the serum did they use for the detection of glucose and lipid metabolism indices at each time point?

Yes, the blood samples were collected at the end of each time point. About 100 ul of blood (which yields about 50 ul serum) were collected through retro-orbital. When sacrificed at postoperative 9 week, all animals were euthanized using CO2 and 500 ul of blood (which yields about 250 ul serum) was collected by eyeball dissection. For the detection of glucose and lipid metabolism, 2-3 ul serum was used for each experiment.

5\. Standard deviation in most of the results is more than the mean values? (Fig. 1, Fig. 3 & Fig. 4)

Yes, according to raw data, these measures vary in different subjects and thus standard deviation may be more than the mean values. In the revised manuscript, we represented results ± SEM in all figures.

6\. Fig. 3b, change in body weights significance between the groups needs to be shown?

We have added the \* and \# to showing the significance.

7\. In the discussion, there is a sentence which says " numerous studies have shown that estrogen......" but only one reference quoted?

We have added more reference.

Reviewer \#2:

In the present study, the authors investigated the role of the Nuclear factor E2-related factor 2 (NRF2), an important oxidative stress sensor that plays regulatory role in energy metabolism, on metabolic parameters of ovariectomized menopausal model.This study is of interest as it addresses an important biological and medical issue. On the whole, the manuscript is sound and well written but I however have some minor concerns that should be addressed by the authors before publication.

1\. Abstract: please include p-value after differences affirmations through the abstract.

We have added the P-value in the abstract.

Materials & methods

2\. The authors took in account the the National Institutes of Health guide for the care and use of Laboratory animals? Please, provide this information

We have added the information.

3\. Statistical analysis: in the present study the authors compared four groups, T-test seems to not be the best way to perform this analysis. ANOVA must be applied. Please, review all numbered sections through the manuscript.

Thanks for the suggestions. We have redone all the statistical analysis. Analyses were performed using Graphpad Prism using one-way ANOVA with Bonferroni\'s Multiple Comparison Test or Kruskal-Wallis test with Dunn\'s Multiple Comparison Test for ordinary or non-parametric data in four groups, as specified in the figure legends and method section.

Results.

4\. Please, provide food intake/energy intake of the animals. Is it hyperphagia presented in ovariectomized mice?

Thanks for the reviewer to provide a very good point that we can do in future. Regretfully, we did not record the food intake of each mice, therefore did not know whether there is hyperphagia presented in the ovariectomzed mice. We would like to explore this in following research for elucidating the detailed mechanisms.

5\. Time-varying maps of metabolic indicators in different groups of animals: what the author's means with "various metabolic substances"? Unclear... please rephrase.

These should be serum LDL, HDL, TG, T-CHO, and GLU, we deleted these unclear phases.

Materials & method.

6.Centrifugation speed should be expressed as g instead of rpm as rpm depends on the diameter of the rotor. Of the centrifuge. Table is available on the web to do this conversion using the speed in rpm and the diameter of the rotor.

We have changed rpm to g.

7\. Materials & methods: Please specify the sensitivity of the assay (i.e. the LOD) and the intra assay coefficient of variation of all ELISA assay.

We add the quality control parameters for all biochemical and ELISA kits, including range, sensitivity, intra and inter CV, and minimal sample volumn for all assays, as a supplementary table.

Results:

8.Were the main white adipose tissue fat pads dissected out to evaluate the adiposity of the animals. Does a greater weight gain in the groups also mean fat accretion?

Thanks for the suggestions. As literature demonstrated that Nrf2 deletion inhibits lipid synthesis, we did not think about that the weight gain is due to fat accretion; therefore did not conduct these adiposity analysis in the initial experimental design. However, this could be useful for our further research.

9\. If the adipose tissue accretion is reduced in some groups (here we need food intake to discuss) there is an "energetic paradox" according to the first law of thermodynamics... (Energy intake = Energy expenditure + Energy stored)

Thanks for the suggestions, we would like to do the related experiments in next step.

10\. Nuclear factor E2-related factor 2 (Nrf2) is a transcription factor that coordinates the basal and stress-inducible activation of a vast array of cytoprotective genes. Understanding the regulation of Nrf2 activity and downstream pathways has major implications for human health, include in menopause woman. In the presented work, the authors showed the impact of NRF2 depletion on oxidative stress but not in antioxidant response. How this could limit the conclusion of the work?

Thanks for the suggestions. Antioxidant response is believed to play regulatory roles in energy metabolism. These experiments may be conducted to analysis related enzymes such as SOD and NQO1 in the KO menopausal mice. However, based on current data, we did not know how the loss of antioxidant response in the KO menopausal mice affect their energy metabolism. We believed this could be a target to further research to elucidate the detailed mechanisms.

11\. Also in discussion section, the evidence of NRF2 and energy metabolism should be clearer.

We add more discussion on Nrf2 and energy metabolism.
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21 Jan 2020

NRF2 deficiency increases obesity susceptibility in a mouse menopausal model

PONE-D-19-25429R1

Dear Dr. Yu,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Vanessa Souza-Mello, Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#2: The authors adequatelly adressed my concern. And in my opinion the manuscript is now acceptable for publication in PlosOne.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#2: Yes: Julio Beltrame Daleprane

10.1371/journal.pone.0228559.r004
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NRF2 deficiency increases obesity susceptibility in a mouse menopausal model

Dear Dr. Yu:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Vanessa Souza-Mello

Academic Editor

PLOS ONE
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